These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39028730)

  • 1. Identifying facilitators and barriers to the uptake of medication for opioid use disorder in Washington, DC: A community-engaged concept mapping approach.
    Gullahorn B; Kuo I; Robinson AM; Bailey J; Loken J; Taggart T
    PLoS One; 2024; 19(7):e0306931. PubMed ID: 39028730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
    Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
    J Gen Intern Med; 2024 Jul; 39(9):1690-1697. PubMed ID: 38587730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
    Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
    J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lived Experiences of Pregnant and Parenting Women in Recovery Toward Medication Treatment for Opioid Use Disorder.
    Titus-Glover D; Shaya FT; Welsh C; Roane L
    Subst Use Addctn J; 2024 Jul; 45(3):367-377. PubMed ID: 38254261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder.
    Fiddian-Green A; Gubrium A; Harrington C; Evans EA
    Int J Environ Res Public Health; 2022 Jul; 19(15):. PubMed ID: 35954700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 11. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers to retention in medications for opioid use disorder treatment in real-world practice.
    Villamil VI; Underwood N; Cremer LJ; Rooks-Peck CR; Jiang X; Guy GP
    J Subst Use Addict Treat; 2024 May; 160():209310. PubMed ID: 38331319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study.
    Welsh JW; Mataczynski MJ; Passetti LL; Hunter BD; Godley MD
    Am J Drug Alcohol Abuse; 2022 May; 48(3):347-355. PubMed ID: 35416739
    [No Abstract]   [Full Text] [Related]  

  • 18. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado.
    Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Amura CR; Cook PF
    J Subst Abuse Treat; 2020 Jul; 114():108027. PubMed ID: 32527514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
    Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.